Q/C Technologies, Inc. (QCLS): EPS (Diluted)

Annual figures by period end, from SEC filings.

Stock splits: 1-for-30, first reflected in a filing dated 2024-04-01; 1-for-97, first reflected in a filing dated 2025-11-19. Figures are as filed: per-share figures and share counts last reported before a split are on the old share basis, so changes and growth rates across a split are not shown. Splits are read from the filings' own restatements, so a share conversion in a merger or reorganization shows up the same way.

-$8.66

Year ended 2025-12-31

2022-12-31 EPS (Diluted) (USD per share) 2025-12-31

Paler bars were last filed before a stock split, on the old share basis.

Period ended	EPS (Diluted)	Change YoY	Source filing
2025-12-31	-$8.66	n/m	2026-04-15, From 2025-01-01
2024-12-31	-$1080.87	n/c	2026-04-15, From 2024-01-01
2023-12-31	-$5.33	n/m	2025-04-11, From 2023-01-01
2022-12-31	-$11.74	n/a	2024-04-01, From 2022-01-01

EPS (Diluted) at similar companies

Companies with the same SEC industry code (In Vitro & In Vivo Diagnostic Substances), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	EPS (Diluted)	Change YoY
Q/C Technologies, Inc. (QCLS)	2025-12-31	-$8.66	n/m
Achieve Life Sciences, Inc. (ACHV)	2025-12-31	-$1.25	n/m
Immucell Corp (ICCC)	2025-12-31	-$0.12	n/m
Anbio Biotechnology (NNNN)	2025-12-31	$0.15	+162.5%
Insight Molecular Diagnostics Inc. (IMDX)	2025-12-31	-$1.65	n/m
Alpha Teknova, Inc. (TKNO)	2025-12-31	-$0.32	n/m
Cardio Diagnostics Holdings, Inc. (CDIO)	2025-12-31	-$3.71	n/m
Volitionrx Ltd (VNRX)	2024-12-31	-$0.31	n/m
Biomerica Inc (BMRA)	2026-05-31	-$1.30	n/m

Compare QCLS, ACHV, ICCC, NNNN side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗